ArticleCureus2024
Peripheral Immune-Mediated Neuropathy Before and During the COVID-19 Pandemic: A Retrospective Cross-Sectional Study in a Referral Center.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are currently seven coronaviruses that can infect humans and the latest addition to these viruses is the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Infection by SARS-CoV-2 is known commonly as coronavirus disease 2019 (COVID-19). Aside from common manifestations of cough and fever, neurologic symptoms such as headache, disturbed consciousness, paresthesia, and seizures have also been seen. By identifying the incidence of peripheral immune-mediated neuropathies (PIMN), early prevention can be made.
methodsThis cross-sectional retrospective analytic study reviewed the case records of patients examined at the Center for Neurodiagnostic and Therapeutic Services (CNS) of Metropolitan Medical Center from January 2018 to December 2021.
resultsThe period incidence of Guillain-Barré Syndrome (GBS) for the years 2018-2019 and 2020-2021 were 9.21% and 24.44%, respectively. The obtained p-value was 0.0226, which was lower than the set p-value of 0.05. Therefore, the period incidence of GBS for 2020-2021 was significantly higher when compared to that of 2018-2019.
conclusionThere has been an increase in cases of GBS during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.